BriaCell says second DSMB recommends continuation of Phase 3 study in MBC

BriaCell (BCTX) Therapeutics announces that the external Data Safety Monitoring Board, an independent group of experts who review and monitor the safety data of the BriaCell clinical study to determine if the study should continue, be modified, or be halted, has completed its second safety data review of BriaCell’s pivotal Phase 3 study of Bria-IMT plus immune checkpoint inhibitor in metastatic breast cancer and recommended continuation of the ongoing study without any modifications. BriaCell’s pivotal Phase 3 study is currently being conducted under Fast Track Designation with the Food and Drug Administration.